SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

Sarepta reported Q3 adjusted EPS of $0.13, below the $0.37 consensus, while revenue fell 4.5% year over year to $381.4 million but beat the $348 million estimate. Elevidys sales were $83.5 million, below the $84.4 million consensus, while PMO revenue exceeded expectations at $240.3 million; shares fell 3.4% after hours. Sarepta raised the low end of 2026 net product revenue guidance by $50 million to $1.25–$1.3 billion, citing PMO strength, and narrowed its adjusted R&D and SG&A expense outlook to $800–$825 million.

Analysis

The key signal is a widening split between Sarepta’s dependable PMO franchise and Elevidys, whose demand remains constrained by the ambulatory-only label. The raised outlook therefore improves near-term revenue visibility, but does not establish that gene-therapy demand has stabilized or that the product can regain a broader addressable population. Watch the mix, not just total guidance: continued PMO outperformance alongside flat Elevidys would support a more mature, lower-upside commercial profile.

The Roche-linked manufacturing revenue is a potential timing and mix cushion, not evidence by itself of stronger end-patient demand. It could make quarterly revenue less informative about U.S. Elevidys uptake; verify whether subsequent Roche shipments translate into ex-U.S. launches and recurring demand before assigning it a durable valuation premium. The lower R&D comparison also overstates operating improvement: it reflects a lapsed milestone and reduced spending after pipeline reprioritization, while SG&A rose.

Near term, the guidance increase and PMO resilience may limit downside after the initial reaction. Over 1–3 months, fourth-quarter product mix and Elevidys volumes are the cleaner commercial tests. Over 6–18 months, the regulatory conversion decisions for Vyondys 53 and Amondys 45 and delayed ENDEAVOR data create discrete catalysts; neither resolves the central Elevidys label and safety question. Contrarian angle: treating this as simply an earnings miss ignores PMO durability, but extrapolating PMO growth to offset Elevidys indefinitely is equally hazardous. ROP has no clear trade implication from the supplied facts.

Key Decisions for Investors

• Keep SRPT neutral rather than chase the post-earnings move. Reassess after the next report: sustained PMO strength with Elevidys flat or declining would challenge the raised-revenue thesis; renewed Elevidys growth would weaken the cautious view.
• For existing SRPT exposure, size risk around binary catalysts rather than treating the expense decline as a margin inflection. Track quarterly product revenue separately from collaboration/manufacturing revenue and verify Roche shipments lead to ex-U.S. commercial demand.
• Set an alert for the first-quarter 2027 ENDEAVOR Cohort 8 data and the FDA decision expected by February 28, 2027. Positive safety data or full approvals could improve the outlook; another delay, restrictive outcome, or evidence of weaker PMO demand would falsify the stabilization case.
• Do not infer a material ROP earnings catalyst from these shipments alone; the article provides no quantified impact on Roche’s consolidated results.